Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07522099
PHASE2

Chinese Adults With Kidney Disease

Sponsor: ADARx Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex mebranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).

Official title: A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-07-23

Completion Date

2028-07-10

Last Updated

2026-04-13

Healthy Volunteers

No

Interventions

DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Telitacicept

fusion protein